Results 61 to 70 of about 109,553 (260)

Repurposing dasatinib for diffuse large B cell lymphoma [PDF]

open access: yesProceedings of the National Academy of Sciences, 2019
To repurpose compounds for diffuse large B cell lymphoma (DLBCL), we screened a library of drugs and other targeted compounds approved by the US Food and Drug Administration on 9 cell lines and validated the results on a panel of 32 genetically characterized DLBCL cell lines.
Scuoppo C   +10 more
openaire   +4 more sources

GelMA‐based 3D spheroids recapitulate transcriptomic and functional hallmarks of myeloid sarcoma

open access: yesFEBS Open Bio, EarlyView.
GelMA 5% hydrogels support the formation of myeloid leukemia spheroids that recapitulate MS‐specific features, including G1 arrest, apoptosis, and ECM‐driven transcriptomic reprogramming. The 3D model mimicked soft‐tissue‐like stiffness and oxygen conditions, and transcriptomic convergence with primary MS samples confirmed its utility as a preclinical ...
Nicolas Germain   +11 more
wiley   +1 more source

Using cell‐free RNA to identify B‐ and T‐cell clonality for diagnosis and monitoring of B‐ and T‐cell neoplasms

open access: yesFEBS Open Bio, EarlyView.
Using peripheral blood for determining B‐cell or T‐cell clonality is more reliable when we use cell‐free RNA (cfRNA) because cells release blood significantly more RNA than DNA. Next‐generation sequencing (NGS) of cfRNA allows us to evaluate fragment cfRNA and evaluate clonality reliably without the need for prior determination of the specific dominant
Adam Albitar   +11 more
wiley   +1 more source

Transformation of diffuse large B-cell lymphoma to lymphoblastic lymphoma

open access: yesJournal of Cancer Research and Therapeutics, 2022
Transformations in diffuse large B-cell lymphoma (DLBCL) are extremely rare. Here, we are presenting a very rare case of DLBCL transforming into lymphoblastic lymphoma (LBL) diagnosed by fine-needle aspiration cytology (FNAC) and flow cytometry.
Pritika, Kushwaha   +5 more
openaire   +2 more sources

The Lupus Damage Index Revision Program: Results From the Item Generation and Reduction Phases

open access: yesArthritis Care &Research, EarlyView.
Objective A data‐driven and expert/patient consensus‐based project to develop a revised Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index (SDI) is under way supported by SLICC, ACR, and the Lupus Foundation of America. Our objective is to report the item generation and reduction phase results
Burak Kundakci   +25 more
wiley   +1 more source

Postmortem Detection of “Clinically Undiagnosed” Diffuse Large B-Cell Lymphoma: Gross and Microscopic Findings

open access: yesDiagnostics
Diffuse large B-cell lymphoma is considered the most found non-Hodgkin lymphoma in adults. Diffuse large B-cell lymphoma, which also occurs in sporadic forms, is associated with some pathological conditions, including human immunodeficiency virus ...
Vincenzo Cianci   +8 more
doaj   +1 more source

Head and Neck Lymphoma in an Iranian Population [PDF]

open access: yesIranian Journal of Otorhinolaryngology, 2017
Introduction: This study is aimed to assess the prevalence and characteristics of head and neck lymphoma in a defined group of an Iranian population.   Materials and Methods: In this retrospective study, 126,450 biopsy reports from two referral Pathology
Nafiseh Shamloo   +5 more
doaj   +1 more source

Fibrin‐associated diffuse large B‐cell lymphoma [PDF]

open access: yesBritish Journal of Haematology, 2019
n ...
Zanelli, Magda   +4 more
openaire   +3 more sources

Pediatric Mediastinal Gray Zone Lymphoma With Germline TET2 Heterozygous Variant

open access: yes
Pediatric Blood &Cancer, EarlyView.
Matthew R. Schuelke   +9 more
wiley   +1 more source

Bio‐Inspired Biopolymeric Implantable Platform for Localized and Sustained Drug Delivery in Solid Tumor Treatment

open access: yesAdvanced Functional Materials, EarlyView.
A bio‐inspired biopolymeric implantable drug delivery platform enables localized and sustained release of 7‐ethyl‐10‐hydroxycamptothecin (SN‐38) in solid tumor treatment. The three‐dimensional (3D) structured crosslinked‐chitosan implants are fabricated via 3D‐printed molds and provide drug release over 3 months, significantly inhibiting tumor growth ...
Mercedes Lozano‐Garcia   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy